Disability

NOVA’s Concierge Medicine Boom is a Game Changer for Patients

CHICAGO, April 10, 2025 /PRNewswire/ -- Home to some of the nation's most renowned hospitals and healthcare research centers, Northern…

8 months ago

Oragenics, Inc. Announces Health and Disability Ethics Committee Submission for Phase IIa Concussion Trial

SARASOTA, Fla., April 09, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel…

9 months ago

GREATER MIAMI JEWISH FEDERATION RELEASES JEWISH MIAMI: A 2024 COMMUNITY STUDY

DEMOGRAPHIC FINDINGS SHOW CONTINUED GROWTH, TREMENDOUS DIVERSITY AND DEEP CONNECTIONS TO ISRAEL AND JEWISH LIFE MIAMI, April 7, 2025 /PRNewswire/…

9 months ago

Sharecare Names Industry Veteran Elizabeth Delahoussaye as Chief Privacy Officer of Health Data Solutions

ATLANTA , April 07, 2025 (GLOBE NEWSWIRE) -- Sharecare, the health tech company that helps to improve care quality, drive…

9 months ago

Lenire Supports Veterans by Sponsoring Hearoes Tour

Lenire proudly sponsors the 10th Annual LexCare Hearing Foundation Hearoes Tour.Lenire is a treatment option for 3.2m veterans living with…

9 months ago

Center for Social Dynamics, Leader in ABA Services, Taps VR Startup to Scale Delivery of ABA Virtual Services

Center for Social Dynamics has selected Floreo to expand delivery of immersive, virtual services incorporating VR autism therapy to schools nationwide.…

9 months ago

Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting

MELBOURNE, Australia and SAN FRANCISCO, April 03, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the…

9 months ago

NervGen Pharma Reports 2024 Year-End Financial Results and Provides Business Updates

Completed enrollment in the chronic cohort and commenced enrollment in the subacute cohort of its Phase 1b/2a clinical trial for…

9 months ago

Covera Health Launches ‘Protect Her™’ – A Breakthrough AI Solution to Advance Early Detection in Women’s Health

New AI-powered platform leverages routine imaging to identify hidden health risks for women as they age, improving quality of life…

9 months ago

Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025

Rybelsus® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and/or chronic…

9 months ago